BridgeBio Pharma, Inc. a new type of biopharmaceutical company focused on genetic diseases, announced that one rapid-fire abstract and two moderated ePosters on the clinical outcomes and quality… read more.
Abbott, a global leader in continuous glucose monitoring (CGM) biowearable technology announced that it has entered a first-of-its-kind agreement to integrate data from its leadiing Libre CGM systems… read more.
AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in… read more.
Vertex Pharmaceuticals announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic… read more.
Rocket Pharmaceuticals a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, announced that the company will be… read more.
BioMarin Pharmaceutical Inc. announced new data from studies of Voxzogo (vosoritide), demonstrating meaningful impact on tibial bowing in children with achondroplasia and investigational early efficacy results in other skeletal… read more.
The FDA has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1… read more.
NICE (UK) is unable to make a recommendation about the use in the NHS of pegylated liposomal irinotecan plus oxaliplatin, 5-fluorouracil and leucovorin for untreated metastatic pancreatic cancer… read more.
Bristol Myers Squibb announced that the FDA approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), the… read more.
UCB announced long-term data from the BE HEARD trials for Bimzelx (bimekizumab) in moderate to severe hidradenitis suppurativa (HS). These two-year data, building on the established efficacy profile… read more.
GSK plc announced the authorisation of Blenrep by the Medicines and Healthcare products Regulatory Agency (MHRA). In the UK, Blenrep is approved for the treatment of adults with… read more.
J&J announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended expanding the Marketing Authorisation for Tremfya (guselkumab) to… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
